Nu Skin Enterprises trades at a deep value multiple (~3x 2026 EBITDA) but faces persistent core business decline and unproven turnaround catalysts. Guidance disappointed, yet management expects margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results